Atossa Therapeutics Presents Data From 40mg Cohort Of Phase 2 EVANGELINE Clinical Trial
Atossa Therapeutics Presents Data From 40mg Cohort Of Phase 2 EVANGELINE Clinical Trial
Atossa Therapeutics 公佈了 40 毫克的 2 期 EVANGELINE 臨床試驗隊列的數據
The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
EVANGELINE的研究正在評估（Z）-內氧芬作爲一種新輔助療法，用於治療患有1級或2級雌激素受體陽性（ER+）/人類表皮生長因子受體2陰性（HER2-）的絕經前女性患者。Atossa是一家臨床階段的生物製藥公司，在腫瘤學中尚未滿足的重大醫療需求領域開發創新藥物，重點是乳腺癌。